dextroamphetamine sulfate 1 MG/ML Oral Solution [ProCentra]

Verify with CMS →

dextroamphetamine sulfate

RxCUI: 884526

Important: Drug coverage and costs vary by plan and location. Verify coverage directly with your Medicare plan before filling a prescription. This is informational data only and should not replace advice from your healthcare provider or pharmacist.
0.2%
Plan Coverage
8
Plans Covering
T2
Avg Tier
0%
Prior Auth Required

What the CMS Formulary Data Shows for dextroamphetamine sulfate 1 MG/ML Oral Solution [ProCentra]

Per the CMS 2026 Part D formulary file, dextroamphetamine sulfate 1 MG/ML Oral Solution [ProCentra] (RxNorm concept RXCUI 884526, generic name dextroamphetamine sulfate) appears on 1 distinct formulary file spanning 8 Medicare Part D plan offerings - 0.2% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 2 to Tier 2, with a cross-plan average of Tier 2.

Real-world access to dextroamphetamine sulfate 1 MG/ML Oral Solution [ProCentra] depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.

Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 9,950 Part D beneficiaries filled dextroamphetamine sulfate 1 MG/ML Oral Solution [ProCentra] in 2023, with total plan-and-beneficiary spending of $5,176,356 and an average per-beneficiary annual cost of $520.24. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry dextroamphetamine sulfate 1 MG/ML Oral Solution [ProCentra] today.

Coverage Details

Formularies covering
1
Plans covering
8
Coverage rate
0.2%
Tier range
Tier 2, Generic
Average tier
Tier 2, Generic

Restrictions

Prior authorization required
0% of formularies
Step therapy required
0% of formularies
Quantity limits
0% of formularies

2023 Medicare Spending

Beneficiaries
9,950
Total spending
$5,176,356
Avg per beneficiary
$520.24

Tier Distribution Across Plans

8 plans
Tier 2, Generic

Medicare Advantage Plans (MA-PD) Covering dextroamphetamine sulfate 1 MG/ML Oral Solution [ProCentra]

8 Medicare Advantage plans with Part D drug coverage include this drug.

Plan Insurer Tier PA Premium States
Network Health Select (PPO) NETWORK HEALTH INSURANCE CORPORATION T2 No $0 WI
Network Health Go (PPO) NETWORK HEALTH INSURANCE CORPORATION T2 No $0 WI
Network Health Anywhere (PPO) NETWORK HEALTH INSURANCE CORPORATION T2 No $0 WI
Network Health Choice (PPO) NETWORK HEALTH INSURANCE CORPORATION T2 No $0 WI
Network Health Zero (PPO) NETWORK HEALTH INSURANCE CORPORATION T2 No $0 WI
Network Health Cares (PPO D-SNP) NETWORK HEALTH INSURANCE CORPORATION T2 No $21.10 WI
Network Health PlusRx (PPO) NETWORK HEALTH INSURANCE CORPORATION T2 No $38.60 WI
Network Health PremierRx (PPO) NETWORK HEALTH INSURANCE CORPORATION T2 No $92.80 WI

Frequently Asked Questions

Is dextroamphetamine sulfate 1 MG/ML Oral Solution [ProCentra] covered by Medicare Part D?

Yes, dextroamphetamine sulfate 1 MG/ML Oral Solution [ProCentra] is covered by 8 Medicare Part D plans (0.2% of all Part D formularies).

What tier is dextroamphetamine sulfate 1 MG/ML Oral Solution [ProCentra] on Medicare Part D plans?

dextroamphetamine sulfate 1 MG/ML Oral Solution [ProCentra] averages Tier 2 across Part D plans, ranging from Tier 2 to Tier 2.

Does dextroamphetamine sulfate 1 MG/ML Oral Solution [ProCentra] require prior authorization?

0% of Part D formularies require prior authorization for dextroamphetamine sulfate 1 MG/ML Oral Solution [ProCentra]. Step therapy: 0%. Quantity limits: 0%.

How much does Medicare spend on dextroamphetamine sulfate 1 MG/ML Oral Solution [ProCentra]?

In 2023, total Medicare Part D spending on dextroamphetamine sulfate 1 MG/ML Oral Solution [ProCentra] was $5,176,356, covering 9,950 beneficiaries. The average spend per beneficiary was $520.24.

Data sourced from the Centers for Medicare & Medicaid Services (CMS). See our methodology for details. Retrieved and formatted by PlainMedicare Editorial